Male Hypoactive Sexual Desire Disorder
Resources for Patients and Caregivers
Male Hypoactive Sexual Desire Disorder (MHSDD) is defined in the DSM-5 as persistent or recurrently deficient sexual or erotic thoughts, fantasies, and desire for sexual activity. These symptoms must have persisted for a minimum of six months, and they must cause clinically significant distress.
Cluster Number:
Wiki Number: 27-Male Hypoactive Sexual Desire Order
Diagnosis:
US Patients:
World Patients:
Sex Ratio:
Age Onset: 3
Brain Area:
Symptoms:
Progression:
Causes:
Medications:
Therapies:
Youtube Video: Increasing Libido in Men:
What To Do and What To Avoid
Amazon or Library Book: Treating Sexual Desire Disorders
Resources for Physicians, Counselors and Researchers
4 CURRENT ARTICLES
FROM PUBMED
The world-wide medical research
reports chosen for each diagnosis
Clicking each title opens the
PubMed article’s summary-abstract.
- The association between erectile dysfunction and depression: a cross-sectional study of 21,139 Brazilian menby Rafael Mathias Pitta on December 19, 2024
CONCLUSION: Erectile dysfunction was an independent and strong factor associated with depression in Brazilian men, highlighting the need for integrated treatment approaches addressing both conditions.
- Association between physical activity levels and lower urinary tract symptoms: a cohort study in 20,732 Brazilian menby Rafael Mathias Pitta on December 19, 2024
CONCLUSION: All physical activity levels were associated with lower odds of lower urinary tract symptoms in 20,732 Brazilian men.
- Promising selective alpha-1 blocker silodosin as a new therapeutic strategy for premature ejaculation and analysis of its drug adverse effect: A systematic review and meta-analysis of randomized controlled trialsby Muhammad Ilham Fauzan on December 18, 2024
CONCLUSIONS: Silodosin significantly increased IELT. However, it also reduced semen ejaculation as its drug adverse effect. This result supports the clinical use of silodosin as an alternative treatment for premature ejaculation.
- Evaluation of the effect of daily tadalafil 5 mg versus daily sildenafil 25 mg on neutrophil-lymphocyte and platelet-lymphocyte ratios in patients with erectile dysfunction: A comparative randomized controlled studyby Abdel Rahman Bakry on December 18, 2024
CONCLUSIONS: Tadalafil and sildenafil have similar clinical efficacy in treating erectile dysfunction. However, tadalafil is more effective in lowering PLR and NLR compared to sildenafil.